Gerresheimer AG (GRRMY)
OTCMKTS
· Delayed Price · Currency is USD
16.70
0.00 (0.00%)
May 6, 2025, 4:00 PM EDT
Gerresheimer AG Revenue
Gerresheimer AG had revenue of 520.05M EUR in the quarter ending February 28, 2025, with 11.57% growth. This brings the company's revenue in the last twelve months to 2.09B, up 4.55% year-over-year. In the fiscal year ending November 30, 2024, Gerresheimer AG had annual revenue of 2.04B with 2.28% growth.
Revenue (ttm)
2.09B EUR
Revenue Growth
+4.55%
P/S Ratio
1.07
Revenue / Employee
172.11K EUR
Employees
12,142
Market Cap
2.32B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2024 | 2.04B | 45.42M | 2.28% |
Nov 30, 2023 | 1.99B | 173.39M | 9.54% |
Nov 30, 2022 | 1.82B | 319.09M | 21.30% |
Nov 30, 2021 | 1.50B | 79.22M | 5.58% |
Nov 30, 2020 | 1.42B | 26.53M | 1.91% |
Nov 30, 2019 | Pro | Pro | Pro |
Nov 30, 2018 | Pro | Pro | Pro |
Nov 30, 2017 | Pro | Pro | Pro |
Nov 30, 2016 | Pro | Pro | Pro |
Nov 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |